{"DataElement":{"publicId":"2934539","version":"1","preferredName":"Acute Myeloid Leukemia Disease Diagnosis Type","preferredDefinition":"the type of acute myeloid leukemia disease that was diagnosed.","longName":"AML_DZ_DX_TP","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2934424","version":"1","preferredName":"Acute Myeloid Leukemia Disease Diagnosis","preferredDefinition":"information relating to the process of identifying acute myeloid leukemia disease (a clonal expansion of myeloid blasts in the bone marrow, blood or other tissues) by the signs and symptoms.","longName":"AML_DZ_DX","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2593592","version":"1","preferredName":"Acute Myeloid Leukemia Diseases and Disorders","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues.  The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized.  The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification).  (WHO, 2001) -- 2003:A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","longName":"C3171:C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28C10733-0450-3B22-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"ONEDATA","dateModified":"2007-02-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2239981","version":"1","preferredName":"Diagnosis","preferredDefinition":"The process of identifying a disease by the signs and symptoms.","longName":"C15220","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diagnosis","conceptCode":"C15220","definition":"The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FD4EEB-1C71-0B27-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-26","modifiedBy":"ONEDATA","dateModified":"2005-06-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"718102B5-75ED-C627-E040-BB89AD432CB2","latestVersionIndicator":"Yes","beginDate":"2009-08-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-19","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2934527","version":"1","preferredName":"Leukemia Diagnosis Type","preferredDefinition":"the type of leukemia that was diagnosed.","longName":"LEUK_DX_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"75","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Leukemia, NOS","valueDescription":"Leukemia","ValueMeaning":{"publicId":"2567354","version":"1","preferredName":"Leukemia","longName":"2567354","preferredDefinition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood.  Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present.  Leukemia is usually associated with anemia, fever, hemorrhagic episodes and splenomegaly.  Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia.  Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leukemia","conceptCode":"C3161","definition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D427-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-18","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-18","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7183CEF2-48A3-A86B-E040-BB89AD436AE3","beginDate":"2009-08-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-19","modifiedBy":"ONEDATA","dateModified":"2009-08-19","deletedIndicator":"No"},{"value":"Polycythemia Vera","valueDescription":"Polycythemia Vera","ValueMeaning":{"publicId":"2838666","version":"1","preferredName":"Polycythemia Vera","longName":"2838666","preferredDefinition":"A chronic myeloproliferative disorder characterized by an increased red blood cell production.  Excessive proliferation of the myeloid lineage is observed as well.  The major symptoms are related to hypertension or to vascular abnormalities caused by the increased red cell mass.  The cause is unknown.  With currently available treatment, the median survival exceeds 10 years.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polycythemia Vera","conceptCode":"C3336","definition":"A chronic myeloproliferative neoplasm characterized by an increased red blood cell production. The bone marrow is hypercellular due to a panmyelotic proliferation typically characterized by pleomorphic megakaryocytes. The major symptoms are related to hypertension, splenomegaly or to episodes of thrombosis and/or hemorrhage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A740CA-960E-2FE1-E040-BB89AD4311CA","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7183CEF2-48AD-A86B-E040-BB89AD436AE3","beginDate":"2009-08-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-19","modifiedBy":"ONEDATA","dateModified":"2009-08-19","deletedIndicator":"No"},{"value":"Essential Thrombocythemia","valueDescription":"Essential Thrombocythemia","ValueMeaning":{"publicId":"2838061","version":"1","preferredName":"Essential Thrombocythemia","longName":"2838061","preferredDefinition":"A chronic myeloproliferative disorder that involves primarily the megakaryocytic lineage and it is characterized by sustained thrombocytosis in the blood, increased numbers of large, mature megakaryocytes in the bone marrow, and episodes of thrombosis and/or hemorrhage.  The cause is unknown.  Median survival times of 10-15 years are commonly reported.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Essential Thrombocythemia","conceptCode":"C3407","definition":"A chronic myeloproliferative neoplasm that involves primarily the megakaryocytic lineage. It is characterized by sustained thrombocytosis in the blood, increased numbers of large, mature megakaryocytes in the bone marrow, and episodes of thrombosis and/or hemorrhage. (WHO, 2008)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62843923-FF56-E9AE-E040-BB89AD435A7B","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7183CEF2-48B8-A86B-E040-BB89AD436AE3","beginDate":"2009-08-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-19","modifiedBy":"ONEDATA","dateModified":"2009-08-19","deletedIndicator":"No"},{"value":"Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive","valueDescription":"Philadelphia Chromosome Positive Chronic Myelogenous Leukemia","ValueMeaning":{"publicId":"2590860","version":"1","preferredName":"Philadelphia Chromosome Positive Chronic Myelogenous Leukemia","longName":"2590860","preferredDefinition":"A chronic myelogenous leukemia characterised by the t(9;22)(q34;q11) chromosomal translocation, resulting in the presence of the Philadelphia chromosome. -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive","conceptCode":"C9128","definition":"A chronic myeloid leukemia characterised by the t(9;22)(q34;q11) chromosomal translocation, resulting in the presence of the Philadelphia chromosome and the BCR-ABL1 fusion gene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28446C9F-B5BA-188F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7183CEF2-48CD-A86B-E040-BB89AD436AE3","beginDate":"2009-08-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-19","modifiedBy":"ONEDATA","dateModified":"2009-08-19","deletedIndicator":"No"},{"value":"Chronic Idiopathic Myelofibrosis","valueDescription":"Chronic Idiopathic Myelofibrosis","ValueMeaning":{"publicId":"2837867","version":"1","preferredName":"Chronic Idiopathic Myelofibrosis","longName":"2837867","preferredDefinition":"A chronic myeloproliferative disorder characterized by bone marrow fibrosis, proliferation of atypical megakaryocytes (micromegakaryocytes) and granulocytes in the bone marrow, anemia, splenomegaly, and extramedullary hematopoiesis.  The cause is unknown.  The median survival time is 3-5 years from diagnosis. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Myelofibrosis","conceptCode":"C2862","definition":"A chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, proliferation of atypical megakaryocytes and granulocytes in the bone marrow, anemia, splenomegaly, and extramedullary hematopoiesis. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6281C75A-49B6-A127-E040-BB89AD431A41","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7183CEF2-48D7-A86B-E040-BB89AD436AE3","beginDate":"2009-08-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-19","modifiedBy":"ONEDATA","dateModified":"2009-08-19","deletedIndicator":"No"},{"value":"Chronic Eosinophilic Leukemia/Hypereosinophilic Syndrome","valueDescription":"Chronic Eosinophilic Leukemia Or Hypereosinophilic Syndrome","ValueMeaning":{"publicId":"2861308","version":"1","preferredName":"Chronic Eosinophilic Leukemia Or Hypereosinophilic Syndrome","longName":"2861308","preferredDefinition":"A rare chronic myeloproliferative disorder characterized by a clonal proliferation of eosinophilic precursors resulting in persistently increased numbers of eosinophils in the blood, marrow and peripheral tissues.  Since acute eosinophilic leukemia is at best exceedingly rare, the term eosinophilic leukemia is normally used as a synonym for chronic eosinophilic leukemia.  In cases in which it is impossible to prove clonality and there is no increase in blast cells, the diagnosis of \"idiopathic hypereosinophilic syndrome\" is preferred.  (WHO, 2001) -- 2003: Or; used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: A syndrome characterized by persistent eosinophilia, for which no underlying cause can be found, and which is associated with signs of organ involvement and dysfunction.  This term has often been applied to cases of chronic eosinophilic leukemia.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Eosinophilic Leukemia, Not Otherwise Specified","conceptCode":"C4563","definition":"A rare myeloproliferative neoplasm characterized by a clonal proliferation of eosinophilic precursors resulting in persistently increased numbers of eosinophils in the blood, marrow and peripheral tissues.  Since acute eosinophilic leukemia is at best exceedingly rare, the term eosinophilic leukemia is normally used as a synonym for chronic eosinophilic leukemia.  In cases in which it is impossible to prove clonality and there is no increase in blast cells, the diagnosis of \"idiopathic hypereosinophilic syndrome\" is preferred.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Idiopathic Hypereosinophilic Syndrome","conceptCode":"C27038","definition":"A syndrome characterized by persistent eosinophilia, for which no underlying cause can be found, and which is associated with signs of organ involvement and dysfunction.  This term has often been applied to cases of chronic eosinophilic leukemia.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67AD9A2F-12D3-E58B-E040-BB89AD437C2B","latestVersionIndicator":"Yes","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7183CEF2-48EC-A86B-E040-BB89AD436AE3","beginDate":"2009-08-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-19","modifiedBy":"ONEDATA","dateModified":"2009-08-19","deletedIndicator":"No"},{"value":"T-Cell Large Granular Lymphocytic Leukemia","valueDescription":"T-Cell Large Granular Lymphocyte Leukemia","ValueMeaning":{"publicId":"2590775","version":"1","preferredName":"T-Cell Large Granular Lymphocyte Leukemia","longName":"2590775","preferredDefinition":"A T-cell peripheral neoplasm characterized by a persistent (>6 months) increase in the number of peripheral blood large granular lymphocytes, without a clearly identified cause. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T-Cell Large Granular Lymphocyte Leukemia","conceptCode":"C4664","definition":"A T-cell peripheral neoplasm characterized by a persistent (>6 months) increase in the number of peripheral blood large granular lymphocytes, without a clearly identified cause. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"27F6CF08-5979-36DF-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7183CEF2-48F7-A86B-E040-BB89AD436AE3","beginDate":"2009-08-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-19","modifiedBy":"ONEDATA","dateModified":"2009-08-19","deletedIndicator":"No"},{"value":"Prolymphocytic Leukemia (B or T-Cell)","valueDescription":"Prolymphocytic Leukemia","ValueMeaning":{"publicId":"2590867","version":"1","preferredName":"Prolymphocytic Leukemia","longName":"2590867","preferredDefinition":"PLL. A type of chronic lymphocyctic leukemia (CLL), in which too many immature white blood cells (prolymphocytes) are found in the blood and bone marrow. PLL usually progresses more rapidly than classic CLL.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prolymphocytic Leukemia","conceptCode":"C3181","definition":"A mature B- or T- cell leukemia with progressive clinical course. It is characterized by the presence of medium-sized lymphocytes with visible nucleoli (prolymphocytes) in the peripheral blood, bone marrow, and spleen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2843C971-29F3-37A6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7183CEF2-490B-A86B-E040-BB89AD436AE3","beginDate":"2009-08-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-19","modifiedBy":"ONEDATA","dateModified":"2009-08-19","deletedIndicator":"No"},{"value":"Hairy Cell Leukemia","valueDescription":"Hairy Cell Leukemia","ValueMeaning":{"publicId":"2838575","version":"1","preferredName":"Hairy Cell Leukemia","longName":"2838575","preferredDefinition":"A rare neoplasm of small B-lymphocytes with \"hairy\" projections in bone marrow, spleen and peripheral blood.  Most patients are middle-aged to elderly adults and present with splenomegaly and pancytopenia. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hairy Cell Leukemia","conceptCode":"C7402","definition":"A neoplasm of small B-lymphocytes with \"hairy\" projections in bone marrow, spleen, and peripheral blood.  Most patients present with splenomegaly and pancytopenia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A51A25-5837-CA49-E040-BB89AD435D3A","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"GDEEN","dateModified":"2023-06-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7183CEF2-4915-A86B-E040-BB89AD436AE3","beginDate":"2009-08-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-19","modifiedBy":"ONEDATA","dateModified":"2009-08-19","deletedIndicator":"No"},{"value":"Chronic Lymphocytic Leukemia, NOS","valueDescription":"Chronic Lymphocytic Leukemia NOS","ValueMeaning":{"publicId":"2573464","version":"1","preferredName":"Chronic Lymphocytic Leukemia NOS","longName":"2573464","preferredDefinition":"Chronic Lymphocytic Leukemia NOS","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EC05-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-15","modifiedBy":"CAMPBELB","dateModified":"2005-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7183CEF2-492A-A86B-E040-BB89AD436AE3","beginDate":"2009-08-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-19","modifiedBy":"ONEDATA","dateModified":"2009-08-19","deletedIndicator":"No"},{"value":"Adult T-Cell Leukemia/Lymphoma","valueDescription":"Adult T-Cell Lymphoma/Leukemia","ValueMeaning":{"publicId":"2836820","version":"1","preferredName":"Adult T-Cell Lymphoma/Leukemia","longName":"2836820","preferredDefinition":"A peripheral (mature) T-cell neoplasm caused by the human T-cell leukemia virus type 1 (HTLV-1).  Adult T-cell lymphoma/leukemia is endemic in several regions of the world, in particular Japan, the Caribbean, and parts of Central Africa. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adult T-Cell Leukemia/Lymphoma","conceptCode":"C3184","definition":"A peripheral (mature) T-cell neoplasm linked to the human T-cell leukemia virus type 1 (HTLV-1).  Adult T-cell leukemia/lymphoma is endemic in several regions of the world, in particular Japan, the Caribbean, and parts of Central Africa.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62470ADA-06CE-83FB-E040-BB89AD436FBF","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7183CEF2-493E-A86B-E040-BB89AD436AE3","beginDate":"2009-08-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-19","modifiedBy":"ONEDATA","dateModified":"2009-08-19","deletedIndicator":"No"},{"value":"Treatment-related Acute Myeloid Leukemia","valueDescription":"Treatment-related Acute Myeloid Leukemia","ValueMeaning":{"publicId":"2934528","version":"1","preferredName":"Treatment-related Acute Myeloid Leukemia","longName":"2934528","preferredDefinition":"Treatment-related Acute Myeloid Leukemia","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7183CEF2-4949-A86B-E040-BB89AD436AE3","latestVersionIndicator":"Yes","beginDate":"2009-08-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7183CEF2-4964-A86B-E040-BB89AD436AE3","beginDate":"2009-08-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-19","modifiedBy":"ONEDATA","dateModified":"2009-08-19","deletedIndicator":"No"},{"value":"Acute Promyelocytic Leukemia","valueDescription":"Acute Promyelocytic Leukemia","ValueMeaning":{"publicId":"2573465","version":"1","preferredName":"Acute Promyelocytic Leukemia","longName":"2573465","preferredDefinition":"Acute Promyelocytic Leukemia","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EC06-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-15","modifiedBy":"CAMPBELB","dateModified":"2005-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7183CEF2-496E-A86B-E040-BB89AD436AE3","beginDate":"2009-08-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-19","modifiedBy":"ONEDATA","dateModified":"2009-08-19","deletedIndicator":"No"},{"value":"Acute Myeloid Leukemia, NOS","valueDescription":"Acute Myeloid Leukemia NOS","ValueMeaning":{"publicId":"2573456","version":"1","preferredName":"Acute Myeloid Leukemia NOS","longName":"2573456","preferredDefinition":"Acute myeloid leukemias that do not fulfill the criteria for inclusion in the group of acute myeloid leukemias which have recurrent genetic abnormalities or myelodysplastic changes, or are therapy-related.  This category includes entities classified according to the French-American-British classification scheme.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia Not Otherwise Specified","conceptCode":"C27753","definition":"Acute myeloid leukemias that do not fulfill the criteria for inclusion in the group of acute myeloid leukemias which have recurrent genetic abnormalities or myelodysplastic changes, or are therapy-related.  This category includes entities classified according to the French-American-British classification scheme.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EBFD-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-15","modifiedBy":"DWARZEL","dateModified":"2019-04-02","changeDescription":"Added Concept Code - DW 04-02-2019","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7183CEF2-4982-A86B-E040-BB89AD436AE3","beginDate":"2009-08-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-19","modifiedBy":"ONEDATA","dateModified":"2009-08-19","deletedIndicator":"No"},{"value":"Precursor T-Lymphoblastic Leukemia (T-Cell ALL)","valueDescription":"Precursor T-Lymphoblastic Leukemia","ValueMeaning":{"publicId":"2590758","version":"1","preferredName":"Precursor T-Lymphoblastic Leukemia","longName":"2590758","preferredDefinition":"This type of acute lymphoblastic leukemia comprises about 15% of childhood cases and 25% of adult cases.  It is more common in males than females.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T Acute Lymphoblastic Leukemia","conceptCode":"C3183","definition":"Acute lymphoblastic leukemia of T-cell origin.  It comprises about 15% of childhood cases and 25% of adult cases.  It is more common in males than females.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"27F3CBD2-0505-469E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7183CEF2-4996-A86B-E040-BB89AD436AE3","beginDate":"2009-08-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-19","modifiedBy":"ONEDATA","dateModified":"2009-08-19","deletedIndicator":"No"},{"value":"Precursor B-Lymphoblastic Leukemia (B-precursor ALL)","valueDescription":"Precursor B-Lymphoblastic Leukemia","ValueMeaning":{"publicId":"2590756","version":"1","preferredName":"Precursor B-Lymphoblastic Leukemia","longName":"2590756","preferredDefinition":"The most frequent type of acute lymphoblastic leukemia.  Approximately 75% of cases occur in children under six years of age.  This is a good prognosis leukemia.  In the pediatric age group the complete remission rate is approximately 95% and the disease free survival rate is 70%.  Approximately 80% of children appear to be cured.  In the adult age group the complete remission rate is 60-85%.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B Acute Lymphoblastic Leukemia","conceptCode":"C8644","definition":"The most frequent type of acute lymphoblastic leukemia.  Approximately 75% of cases occur in children under six years of age.  This is a good prognosis leukemia.  In the pediatric age group the complete remission rate is approximately 95% and the disease free survival rate is 70%.  Approximately 80% of children appear to be cured.  In the adult age group the complete remission rate is 60-85%.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"27F3CBD2-04DE-469E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7183CEF2-49AA-A86B-E040-BB89AD436AE3","beginDate":"2009-08-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-19","modifiedBy":"ONEDATA","dateModified":"2009-08-19","deletedIndicator":"No"},{"value":"Acute Lymphoblastic Leukemia, NOS","valueDescription":"Acute Lymphoblastic Leukemia, NOS","ValueMeaning":{"publicId":"2934529","version":"1","preferredName":"Acute Lymphoblastic Leukemia, NOS","longName":"2934529","preferredDefinition":"A leukemia with an acute onset, characterized by the presence of lymphoblasts or Burkitt cells in the bone marrow and the peripheral blood. It includes the precursor B lymphoblastic leukemia, precursor T lymphoblastic leukemia, and Burkitt's leukemia, NOS (not otherwise specified).","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7183CEF2-49B4-A86B-E040-BB89AD436AE3","latestVersionIndicator":"Yes","beginDate":"2009-08-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7183CEF2-49CD-A86B-E040-BB89AD436AE3","beginDate":"2009-08-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-19","modifiedBy":"ONEDATA","dateModified":"2009-08-19","deletedIndicator":"No"},{"value":"Leukemia Miscellaneous","valueDescription":"Leukemia","ValueMeaning":{"publicId":"2567354","version":"1","preferredName":"Leukemia","longName":"2567354","preferredDefinition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood.  Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present.  Leukemia is usually associated with anemia, fever, hemorrhagic episodes and splenomegaly.  Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia.  Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leukemia","conceptCode":"C3161","definition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D427-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-18","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-18","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7183CEF2-49E1-A86B-E040-BB89AD436AE3","beginDate":"2009-08-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-19","modifiedBy":"ONEDATA","dateModified":"2009-08-19","deletedIndicator":"No"},{"value":"Chronic Myeloproliferative Disease","valueDescription":"Chronic Myeloproliferative Disorder","ValueMeaning":{"publicId":"2590870","version":"1","preferredName":"Chronic Myeloproliferative Disorder","longName":"2590870","preferredDefinition":"Chronic myeloproliferative disorders (CMPDs) are clonal hematopoietic stem cell disorders, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, and megakaryocytic) lineages.  The proliferation is associated with relatively normal, effective maturation, resulting in increased numbers of granulocytes, red blood cells, and/or platelets in the peripheral blood.  CMPDs are primarily diseases of adults.  -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myeloproliferative Neoplasm","conceptCode":"C4345","definition":"A group of myeloid neoplasms that includes the following: chronic myeloid leukemia, BCR-ABL1 positive; polycythemia vera; essential thrombocythemia;  primary myelofibrosis; chronic neutrophilic leukemia; chronic eosinophilic leukemia, not otherwise specified; and myeloproliferative neoplasm, unclassifiable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28454156-4895-574D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7183CEF2-49F5-A86B-E040-BB89AD436AE3","beginDate":"2009-08-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-19","modifiedBy":"ONEDATA","dateModified":"2009-08-19","deletedIndicator":"No"},{"value":"Chronic Lymphoid Leukemia","valueDescription":"CLL","ValueMeaning":{"publicId":"2590865","version":"1","preferredName":"CLL","longName":"2590865","preferredDefinition":"The most common type of chronic lymphoid leukemia, and comprises 90% of chronic lymphoid leukemias in the United States.  Morphologically, the neoplastic cells are small, round B-lymphocytes.  The clinical course is indolent, but this type of leukemia is not considered to be curable with available therapy. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Lymphocytic Leukemia","conceptCode":"C3163","definition":"The most common type of chronic lymphoid leukemia.  It comprises 90% of chronic lymphoid leukemias in the United States.  Morphologically, the neoplastic cells are small, round B-lymphocytes.  This type of leukemia is not considered to be curable with available therapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2843C971-29AB-37A6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7183CEF2-4A09-A86B-E040-BB89AD436AE3","beginDate":"2009-08-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-19","modifiedBy":"ONEDATA","dateModified":"2009-08-19","deletedIndicator":"No"},{"value":"Acute Myeloid Leukemia","valueDescription":"Acute Myeloid Leukemia","ValueMeaning":{"publicId":"2581275","version":"1","preferredName":"Acute Myeloid Leukemia","longName":"2581275","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues.  The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized.  The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification).  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A88-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"ONEDATA","dateModified":"2006-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7183CEF2-4A13-A86B-E040-BB89AD436AE3","beginDate":"2009-08-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-19","modifiedBy":"ONEDATA","dateModified":"2009-08-19","deletedIndicator":"No"},{"value":"Acute Lymphoblastic Leukemia","valueDescription":"ALL","ValueMeaning":{"publicId":"2573071","version":"1","preferredName":"ALL","longName":"2573071","preferredDefinition":"A leukemia with an acute onset, characterized by the presence of lymphoblasts or Burkitt cells in the bone marrow and the peripheral blood.  It includes the precursor B lymphoblastic leukemia, precursor T lymphoblastic leukemia, and Burkitt's leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Lymphoblastic Leukemia","conceptCode":"C3167","definition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EA7C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-04","endDate":null,"createdBy":"KLINGERK","dateCreated":"2005-02-04","modifiedBy":"KUMMEROA","dateModified":"2022-06-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7183CEF2-4A27-A86B-E040-BB89AD436AE3","beginDate":"2009-08-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-19","modifiedBy":"ONEDATA","dateModified":"2009-08-19","deletedIndicator":"No"},{"value":"Down Syndrome Acute Myeloid Leukemia (AML)","valueDescription":"Down Syndrome Acute Myeloid Leukemia","ValueMeaning":{"publicId":"7640500","version":"1","preferredName":"Down Syndrome Acute Myeloid Leukemia","longName":"7640500","preferredDefinition":"A disorder caused by the presence of an extra chromosome 21 and characterized by mental retardation and distinguishing physical features.: A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Down Syndrome","conceptCode":"C2993","definition":"A chromosomal dysgenesis syndrome resulting from a triplication or translocation of chromosome 21. Down syndrome occurs in approximately 1:700 live births. Abnormalities are variable from individual to individual and may include mental retardation, retarded growth, flat hypoplastic face with short nose, prominent epicanthic skin folds, small low-set ears with prominent antihelix, fissured and thickened tongue, laxness of joint ligaments, pelvic dysplasia, broad hands and feet, stubby fingers, transverse palmar crease, lenticular opacities and heart disease. Patients with Down syndrome have an estimated 10 to 30-fold increased risk for leukemia; most have symptoms of Alzheimer's disease by age 40. Also known as trisomy 21 syndrome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0AB1BBB-CC88-5EAE-E053-4EBD850A5DB1","latestVersionIndicator":"Yes","beginDate":"2021-04-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2021-04-23","modifiedBy":"ONEDATA","dateModified":"2021-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C0AB1BBB-CCA1-5EAE-E053-4EBD850A5DB1","beginDate":"2021-04-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2021-04-23","modifiedBy":"ONEDATA","dateModified":"2021-04-23","deletedIndicator":"No"},{"value":"Mixed Phenotype Acute Leukemia (MPAL)","valueDescription":"Mixed Phenotype Acute Leukemia","ValueMeaning":{"publicId":"7000422","version":"1","preferredName":"Mixed Phenotype Acute Leukemia","longName":"7000422","preferredDefinition":"An acute leukemia of ambiguous lineage.  It is characterized by the presence of either separate populations of blasts of more than one lineage, or one population of blasts co-expressing markers of more than one lineage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mixed Phenotype Acute Leukemia","conceptCode":"C82179","definition":"An acute leukemia of ambiguous lineage.  It is characterized by the presence of either separate populations of blasts of more than one lineage, or one population of blasts co-expressing markers of more than one lineage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"950E57BC-8DF0-20B0-E053-F662850A4478","latestVersionIndicator":"Yes","beginDate":"2019-10-16","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-10-16","modifiedBy":"KUMMEROA","dateModified":"2023-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C0AB2066-AEF5-031B-E053-4EBD850A9647","beginDate":"2021-04-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2021-04-23","modifiedBy":"ONEDATA","dateModified":"2021-04-23","deletedIndicator":"No"},{"value":"B-ALL","valueDescription":"B Acute Lymphoblastic Leukemia","ValueMeaning":{"publicId":"4263974","version":"1","preferredName":"B Acute Lymphoblastic Leukemia","longName":"4263974","preferredDefinition":"The most frequent type of acute lymphoblastic leukemia.  Approximately 75% of cases occur in children under six years of age.  This is a good prognosis leukemia.  In the pediatric age group the complete remission rate is approximately 95% and the disease free survival rate is 70%.  Approximately 80% of children appear to be cured.  In the adult age group the complete remission rate is 60-85%.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B Acute Lymphoblastic Leukemia","conceptCode":"C8644","definition":"The most frequent type of acute lymphoblastic leukemia.  Approximately 75% of cases occur in children under six years of age.  This is a good prognosis leukemia.  In the pediatric age group the complete remission rate is approximately 95% and the disease free survival rate is 70%.  Approximately 80% of children appear to be cured.  In the adult age group the complete remission rate is 60-85%.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F63DCAA0-1156-5D4B-E040-BB89AD432C9C","latestVersionIndicator":"Yes","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DB1279AB-E78F-440D-E053-4EBD850AFB27","beginDate":"2022-03-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2022-03-25","modifiedBy":"ONEDATA","dateModified":"2022-03-25","deletedIndicator":"No"},{"value":"T-ALL","valueDescription":"T Acute Lymphoblastic Leukemia","ValueMeaning":{"publicId":"4263973","version":"1","preferredName":"T Acute Lymphoblastic Leukemia","longName":"4263973","preferredDefinition":"Acute lymphoblastic leukemia of T-cell origin.  It comprises about 15% of childhood cases and 25% of adult cases.  It is more common in males than females.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T Acute Lymphoblastic Leukemia","conceptCode":"C3183","definition":"Acute lymphoblastic leukemia of T-cell origin.  It comprises about 15% of childhood cases and 25% of adult cases.  It is more common in males than females.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F63DCAA0-1133-5D4B-E040-BB89AD432C9C","latestVersionIndicator":"Yes","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DB1279AB-E799-440D-E053-4EBD850AFB27","beginDate":"2022-03-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2022-03-25","modifiedBy":"ONEDATA","dateModified":"2022-03-25","deletedIndicator":"No"},{"value":"Myelodysplastic Syndrome","valueDescription":null,"ValueMeaning":{"publicId":"3946618","version":"1","preferredName":"Myelodysplastic Syndrome","longName":"3946618","preferredDefinition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome","conceptCode":"C3247","definition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA87B0E5-6712-6876-E040-BB89AD437204","latestVersionIndicator":"Yes","beginDate":"2013-11-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-11-06","modifiedBy":"GDEEN","dateModified":"2022-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DF254FDB-2479-0788-E053-731AD00A68DE","beginDate":"2022-05-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-05-18","modifiedBy":"MMADDINENI","dateModified":"2022-05-18","deletedIndicator":"No"},{"value":"Therapy-related Acute Myeloid Leukemia","valueDescription":null,"ValueMeaning":{"publicId":"4858058","version":"1","preferredName":"Therapy-Related Acute Myeloid Leukemia","longName":"4858058","preferredDefinition":"An acute myeloid leukemia arising as a result of the mutagenic effect of chemotherapy agents and/or ionizing radiation.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia Post Cytotoxic Therapy","conceptCode":"C8252","definition":"An acute myeloid leukemia arising as a result of the mutagenic effect of chemotherapy agents and/or ionizing radiation.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1805D4A1-423A-4FE2-E050-BB89AD435E9B","latestVersionIndicator":"Yes","beginDate":"2015-06-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DF254FDB-247A-0788-E053-731AD00A68DE","beginDate":"2022-05-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-05-18","modifiedBy":"MMADDINENI","dateModified":"2022-05-18","deletedIndicator":"No"},{"value":"Mixed Phenotype Acute Leukemia","valueDescription":null,"ValueMeaning":{"publicId":"7000422","version":"1","preferredName":"Mixed Phenotype Acute Leukemia","longName":"7000422","preferredDefinition":"An acute leukemia of ambiguous lineage.  It is characterized by the presence of either separate populations of blasts of more than one lineage, or one population of blasts co-expressing markers of more than one lineage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mixed Phenotype Acute Leukemia","conceptCode":"C82179","definition":"An acute leukemia of ambiguous lineage.  It is characterized by the presence of either separate populations of blasts of more than one lineage, or one population of blasts co-expressing markers of more than one lineage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"950E57BC-8DF0-20B0-E053-F662850A4478","latestVersionIndicator":"Yes","beginDate":"2019-10-16","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-10-16","modifiedBy":"KUMMEROA","dateModified":"2023-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DF254FDB-247B-0788-E053-731AD00A68DE","beginDate":"2022-05-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-05-18","modifiedBy":"MMADDINENI","dateModified":"2022-05-18","deletedIndicator":"No"},{"value":"Therapy-related Myelodysplastic Syndrome","valueDescription":null,"ValueMeaning":{"publicId":"10425591","version":"1","preferredName":"Therapy-Related Myelodysplastic Syndrome","longName":"10425591v1.00","preferredDefinition":"A myelodysplastic syndrome caused by chemotherapy and/or radiotherapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome Post Cytotoxic Therapy","conceptCode":"C27722","definition":"A myelodysplastic syndrome resulting from chemotherapy or radiation therapy for cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFC1DD82-6712-2FB8-E053-731AD00AE15F","latestVersionIndicator":"Yes","beginDate":"2022-06-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-08","modifiedBy":"KUMMEROA","dateModified":"2022-06-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DFC1DD82-6713-2FB8-E053-731AD00AE15F","beginDate":"2022-06-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-06-08","modifiedBy":"KUMMEROA","dateModified":"2022-06-08","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AMC CRF:AIDS Malignancy Consortium Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7183CEF2-488F-A86B-E040-BB89AD436AE3","latestVersionIndicator":"Yes","beginDate":"2009-08-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-19","modifiedBy":"KUMMEROA","dateModified":"2022-06-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"SUPPMH_QVAL_MHTERM","type":"COG Form Element","context":"COG"}],"ReferenceDocuments":[{"name":"Acute Myeloid Leukemia","type":"Preferred Question Text","description":"Acute Myeloid Leukemia","url":null,"context":"CTEP"},{"name":"COG AQT1","type":"Alternate Question Text","description":"Which diagnosis does this patient have?","url":null,"context":"COG"}],"origin":"AMC CRF:AIDS Malignancy Consortium Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"71844410-7F65-DC0F-E040-BB89AD43404C","latestVersionIndicator":"Yes","beginDate":"2009-08-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-19","modifiedBy":"DWARZEL","dateModified":"2022-05-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}